Vericel
This content is intended for Health Care Professionals in the United States.
Vericel develops, manufactures, and markets autologous cell-based therapies for patients with serious diseases and conditions. Vericel markets MACI® (autologous cultured chondrocytes on porcine collagen membrane) for the repair of symptomatic, full-thickness cartilage defects of the knee in adult patients. MACI is the first FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient’s own knee.
For more information, please visit MACI.com.
MACI Case Study Discussion: 34yo Male - Trochlear Defect
By
Vericel
FEATURING
Jason Rand
By
Vericel
FEATURING
Jason Rand
Jason Rand, PA discusses a 34yo male with a trochlear defect and the treatment approach
Comments 0
Login to view comments.
Click here to Login
